• Tue news: Obesity pill race heats up. Express Scripts sues FTC. More ESMO data. Kairos IPO. Daiichi-Merck guided-missile cancer drug. See more on our front page

Prothena rolls out preclinical data for anti-amyloid Alzheimer's candidate to rival...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 26, 2021 at 10:22: PM
via The build up of amyloid-beta in the brain has been a prime target of Alzheimer's drug developers, including Biogen with its controversial new drug Aduhelm, which was granted the go-ahead from the FDA in early June. Now Biogen competitor Prothena says its own monoclonal antibody binds to amyloid-beta with about 11 times more strength than Aduhelm (aducanumab).

article source
 




Similar threads

cafead
Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy
Replies
0
Views
92
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS makes quickfire bets on neurodegeneration, paying $95M to exercise Evotec, Prothena options
Replies
0
Views
86
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Prothena leverages Walgreens’ capabilities to accelerate development of Alzheimer’s Drug
Replies
0
Views
209
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Prothena: Trial data underscores the potential of antibody in treating Alzheimer’s disease
Replies
0
Views
117
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA grants Prothena fast track designation for Alzheimer’s disease therapy
Replies
0
Views
179
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote